menu

Pulse Points in Prostate Cancer: Embracing Advances with PARPi Combinations

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Pulse Points in Prostate Cancer: Embracing Advances with PARPi Combinations

close
0.75 credits
45 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.75 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    During recent years, advances in the understanding of the underlying genetic events and biology in prostate cancer development, including the DDR and MMR pathway alterations, have yielded new avenues for clinical exploration. Prostate cancers with deleterious aberrations in DNA damage repair (DDR) genes, including homologous recombination repair, such as mutations in BRCA1/2 and ATM, are associated with response to poly (adenosine diphosphate–ribose) polymerase (PARP) inhibition.

    PARP inhibitors are now gaining FDA approvals for the treatment of patients with mCRPC, and ongoing clinical trials are evaluating these PARP inhibitors as monotherapy or in combination with other treatments such as androgen pathway inhibitors. The National Comprehensive Cancer Network (NCCN®) is now recommending germline testing and molecular biomarker analysis, including tumor testing for HRR mutations, and to consider tumor testing for MSI or dMMR for metastatic disease. PARP inhibitors for the treatment of mCRPC in patients harboring germline and somatic BRCA/ATM mutations, and in combination with androgen pathway inhibition, are poised to propel the management of mCRPC toward a more personalized approach.

    In this activity, expert faculty will review, discuss, and provide their expert insights on recent and emerging practice-changing advancements with PARP inhibitors for the treatment of mCRPC, with a focus on PARP inhibition with androgen pathway inhibition combination treatment.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Describe the significance of testing for DNA damage repair (DDR) pathway mutations in mCRPC to guide treatment decisions
    • Discuss the rationale for combining PARP inhibition with androgen pathway inhibition for the treatment of mCRPC
    • Evaluate recent clinical efficacy data and ongoing clinical trials for PARP inhibitor combinations in mCRPC
  • Target Audience

    This activity is intended for US and global medical oncologists, urologists, pathologists, oncology/urology advanced practitioners (nurses, physician assistants, pharmacists, laboratory professionals), and other healthcare professionals involved in the treatment of prostate cancer.

  • Faculty Disclosure

    Disclosure of Conflict of Interest 
    AXIS Medical Education requires faculty, instructors, authors, planners, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. All identified conflicts of interest are thoroughly vetted and mitigated by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and mitigate all conflicts of interestthat faculty and authors disclose prior to an educational activity being delivered/presented to learners. AXIS will identify, review, and mitigate all conflicts of interestthat activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to initiation of the planning phase for an educational activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided for this activity.

    The faculty reported the following financial relationships or relationships they have with ineligible companies of any amount during the past 24 months. Neeraj Agarwal, MD, reported a financial interest/relationship or affiliation in the form of Consultant: Astellas Pharma US, Inc; AstraZeneca Pharmaceuticals LP; AVEO Pharmaceuticals, Inc; Bayer HealthCare, Inc; Bristol-Myers Squibb Co; Calithera Biosciences Inc; Clovis Oncology; Eisai Inc; Eli Lilly and Co; EMD Serono, Inc; Exelixis, Inc; Foundation Medicine; Genentech, Inc; Janssen Oncology; Merck & Co, Inc; MEI Pharma; Nektar Therapeutics; Novartis Pharmaceuticals Corp; Pfizer, Inc; Pharmacyclics, Inc; and Seattle Genetics, Inc. Johann de Bono, MB, ChB FRCP, MSc, PhD, FMedSci reported a financial interest/relationship or affiliation in the form of Advisory board,  Served as a speaker, and Contracted research: AstraZeneca Pharmaceuticals LP; Astellas Pharma US, Inc; Bayer HealthCare, Inc; Bioxcel Therapeutics; Boehringer Ingelheiml Cellcentric; Daiichi Sankyo Company, Ltd; Eisai Inc; Genentech/Roche; Genmab; GlaxoSmithKline; Janssen Oncology; Merck Serano; Merck Sharp & Dohme; Menarini/Silicon Biosystems; Orion; Pfizer, Inc; Qiagen; Sanofi-aventis; Sierra Oncology; Taiho Pharmaceutical Co, Ltd; Terumo; and Vertex Pharmaceuticals. Research funding to IRC: AstraZeneca Pharmaceuticals LP; Astellas Pharma US, Inc; Bayer HealthCare, Inc; Cellcentric; Daiichi Sankyo Co, Ltd; Genentech, Inc; Genmab; GlaxoSmithKline; Janssen Oncology; Merck Serano; Merck Sharp & Dohme; Orion; Sanofi-aventis; Sierra Oncology; Taiho Pharmaceutical Co, Ltd; Pfizer, Inc; and Vertex Pharmaceuticals. Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck.

    The planners, directors, managers, peer reviewers, and relevant staff  reported the following financial relationships they have ineligible companies of any amount during the past 24 months: Linda Gracie-King, MS: Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC;  Adrienne N. Nedved, PharmD., MPA., BCOP; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships to products or devices with any ineligible company. Robert Mocharnuk, MD, reports a financial interest/relationship or affiliation in the form of Common stock: Merck.

  • Accreditation and Credit Designation Statements

    ACCREDITED CONTINUING  EDUCATION
    Accreditation Statement

    ReachMD Healthcare ImageIn support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    ReachMD Healthcare ImageThis activity was planned by and for the healthcare team, and learners will receive  0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of  0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ReachMD Healthcare ImageCredit Designation for Physician Assistants
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 4/28/2022. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for for 0.75  contact hour of continuing pharmacy education credit JA4008106-0000-21-020-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.75  contact hour.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Laboratory Professionals
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 0.75  CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.

  • Provider(s)/Educational Partner(s)

    Provided by ReachMD Healthcare Image

  • Commercial Support

    This activity is supported by an educational grant from Pfizer Inc.

  • Terms of Use

    Disclosure of Unlabeled Use        
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Disclaimer      
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Method of Participation and Request for Credit:     
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    During recent years, advances in the understanding of the underlying genetic events and biology in prostate cancer development, including the DDR and MMR pathway alterations, have yielded new avenues for clinical exploration. Prostate cancers with deleterious aberrations in DNA damage repair (DDR) genes, including homologous recombination repair, such as mutations in BRCA1/2 and ATM, are associated with response to poly (adenosine diphosphate–ribose) polymerase (PARP) inhibition.

    PARP inhibitors are now gaining FDA approvals for the treatment of patients with mCRPC, and ongoing clinical trials are evaluating these PARP inhibitors as monotherapy or in combination with other treatments such as androgen pathway inhibitors. The National Comprehensive Cancer Network (NCCN®) is now recommending germline testing and molecular biomarker analysis, including tumor testing for HRR mutations, and to consider tumor testing for MSI or dMMR for metastatic disease. PARP inhibitors for the treatment of mCRPC in patients harboring germline and somatic BRCA/ATM mutations, and in combination with androgen pathway inhibition, are poised to propel the management of mCRPC toward a more personalized approach.

    In this activity, expert faculty will review, discuss, and provide their expert insights on recent and emerging practice-changing advancements with PARP inhibitors for the treatment of mCRPC, with a focus on PARP inhibition with androgen pathway inhibition combination treatment.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Describe the significance of testing for DNA damage repair (DDR) pathway mutations in mCRPC to guide treatment decisions
    • Discuss the rationale for combining PARP inhibition with androgen pathway inhibition for the treatment of mCRPC
    • Evaluate recent clinical efficacy data and ongoing clinical trials for PARP inhibitor combinations in mCRPC
  • Target Audience

    This activity is intended for US and global medical oncologists, urologists, pathologists, oncology/urology advanced practitioners (nurses, physician assistants, pharmacists, laboratory professionals), and other healthcare professionals involved in the treatment of prostate cancer.

  • Faculty Disclosure

    Disclosure of Conflict of Interest 
    AXIS Medical Education requires faculty, instructors, authors, planners, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. All identified conflicts of interest are thoroughly vetted and mitigated by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and mitigate all conflicts of interestthat faculty and authors disclose prior to an educational activity being delivered/presented to learners. AXIS will identify, review, and mitigate all conflicts of interestthat activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to initiation of the planning phase for an educational activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided for this activity.

    The faculty reported the following financial relationships or relationships they have with ineligible companies of any amount during the past 24 months. Neeraj Agarwal, MD, reported a financial interest/relationship or affiliation in the form of Consultant: Astellas Pharma US, Inc; AstraZeneca Pharmaceuticals LP; AVEO Pharmaceuticals, Inc; Bayer HealthCare, Inc; Bristol-Myers Squibb Co; Calithera Biosciences Inc; Clovis Oncology; Eisai Inc; Eli Lilly and Co; EMD Serono, Inc; Exelixis, Inc; Foundation Medicine; Genentech, Inc; Janssen Oncology; Merck & Co, Inc; MEI Pharma; Nektar Therapeutics; Novartis Pharmaceuticals Corp; Pfizer, Inc; Pharmacyclics, Inc; and Seattle Genetics, Inc. Johann de Bono, MB, ChB FRCP, MSc, PhD, FMedSci reported a financial interest/relationship or affiliation in the form of Advisory board,  Served as a speaker, and Contracted research: AstraZeneca Pharmaceuticals LP; Astellas Pharma US, Inc; Bayer HealthCare, Inc; Bioxcel Therapeutics; Boehringer Ingelheiml Cellcentric; Daiichi Sankyo Company, Ltd; Eisai Inc; Genentech/Roche; Genmab; GlaxoSmithKline; Janssen Oncology; Merck Serano; Merck Sharp & Dohme; Menarini/Silicon Biosystems; Orion; Pfizer, Inc; Qiagen; Sanofi-aventis; Sierra Oncology; Taiho Pharmaceutical Co, Ltd; Terumo; and Vertex Pharmaceuticals. Research funding to IRC: AstraZeneca Pharmaceuticals LP; Astellas Pharma US, Inc; Bayer HealthCare, Inc; Cellcentric; Daiichi Sankyo Co, Ltd; Genentech, Inc; Genmab; GlaxoSmithKline; Janssen Oncology; Merck Serano; Merck Sharp & Dohme; Orion; Sanofi-aventis; Sierra Oncology; Taiho Pharmaceutical Co, Ltd; Pfizer, Inc; and Vertex Pharmaceuticals. Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck.

    The planners, directors, managers, peer reviewers, and relevant staff  reported the following financial relationships they have ineligible companies of any amount during the past 24 months: Linda Gracie-King, MS: Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC;  Adrienne N. Nedved, PharmD., MPA., BCOP; and Dee Morgillo, MEd, MT(ASCP), CHCP hereby state that they do not have any financial relationships or relationships to products or devices with any ineligible company. Robert Mocharnuk, MD, reports a financial interest/relationship or affiliation in the form of Common stock: Merck.

  • Accreditation and Credit Designation Statements

    ACCREDITED CONTINUING  EDUCATION
    Accreditation Statement

    ReachMD Healthcare ImageIn support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    ReachMD Healthcare ImageThis activity was planned by and for the healthcare team, and learners will receive  0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of  0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ReachMD Healthcare ImageCredit Designation for Physician Assistants
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 4/28/2022. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for for 0.75  contact hour of continuing pharmacy education credit JA4008106-0000-21-020-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.75  contact hour.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Laboratory Professionals
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 0.75  CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program.

  • Provider(s)/Educational Partner(s)

    Provided by ReachMD Healthcare Image

  • Commercial Support

    This activity is supported by an educational grant from Pfizer Inc.

  • Terms of Use

    Disclosure of Unlabeled Use        
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Disclaimer      
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Method of Participation and Request for Credit:     
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Programs 9/19/21